Pasqual Maragall Foundation, Banc de Sang i Teixits, Dr Oriol Mitjà and Andreu Mas-Colell have been selected as winners of the third edition of the Trifermed Awards for social impact in healthcare. The ceremony was held on June 14th at CaixaForum Barcelona with the participation of more than 300 attendees from the local and international sector.

The prizes are chaired by the researcher and neurobiologist Dra. Mara Dierseen (winner of 2017). In addition to the Dra. Dierssen, the jury was made up of Ignasi Biosca (Reig Jofre and former president of CataloniaBio), Clara Campàs (Kern Pharma and Asabys Partners), Luis ...

Catalan biomedical companies attracted €102 million in investment in 2017, with €3.4 million per operation, on average. This will allow them to push forward in the development of drugs and innovative medical technology, as reflected in the Study on investment in the Biomedical industry in Catalonia: Achievements and future challenges presented today by CataloniaBio & HealthTech and EY in Barcelona. The event drew a crowd of more than 60 entrepreneurs, investors and professionals from the sector.

Venture capital continues to be the main source of funding for companies that develop products (33%), while service firms tend to opt for ...

Hospital Clinic Barcelona has launched a 3D bioprinting laboratory, through a collaboration with Avinent, to print prototypes and parts for traumatology, maxillofacial surgery, otorhinolaryngology, neurosurgery and neonatology.

The lack of harmonised regulations and effective controls means this technique can't be used in patients yet, but it is a big step forward in terms of the advantages 3D printing has to offer for surgery.

Recently, Avinent was at the BIOMEDevice congress and on abusiness mission to Boston to get a first-hand look at the most innovative technology being applied in this field and to explore commercialisation opportunities.

More information

Photo ...

Venture capital firm Inveready, a CataloniaBio & HealthTech member, is putting the finishing touches on a €25-million fund to invest in start-ups in the health and biotechnology arena. The fund will be launched in the coming weeks, according to information from Expansión. 

With this third vehicle coming soon, to be called Biotech III, Inveready will manage more than €175 million in investment. In total, they hope to build a portfolio of 20 to 25 companies, mainly in Spain. 

Photo: Sara Secall and Roger Piqué at the Inveready headquarters in Barcelona - © Expansión, Elena Ramón

Banco Sabadell and Asabys Partners, founded by Josep Lluís Sanfeliu and Clara Campàs —member of the last Board of directors at CataloniaBio (2014-2018)—, have created a new venture capital fund of 60 million euros which will centre its investment activity in the health arena.

The new fund is known as Sabadell Asabys Health Innovation Fund. It will carry out initial investments in biotech, MedTech and digital health companies in Spain, as well as the UK and Israel.

The fund could obtain up to 6 million euros per company, and expects to work closely with research centres and benchmark ...

Bionure, member of CataloniaBio & HealthTech that develops neuroprotectant agents to treat neurodegenerative diseases primarily focusing on rare ophthalmologic diseases as Acute Optic Neuritis (AON) and Neuromyelitis Optica (NMO), announces the initiation of a Phase I clinical trial of its lead compound BN201 in the United Kingdom.

BN201 is a first-in-class selective SGK2 agonist that promotes remyelination and neuroprotection, offering a game-changing solution for neurodegenerative diseases.

The company has reconstituted its Board of Directors and added prominent neuro-ophthalmologist Dr. Craig Smith as the new Chief Medical Officer (CMO). Dr Smith is a Senior Advisor/Consultant with the Bill and Melinda ...

For five months, a total of eleven emerging companies will receive free training and guidance...

Bicosome, a CataloniaBio & HealthTech member that has developed technology to... 

Kiversal, a CataloniaBio & HealthTech member, has been awarded a €182,000 grant from the 2017 Neotec programme...

Mitelos, member of CataloniaBio & HealthTech, has signed a partnership agreement with Glenmark Pharmaceuticals Ltd to...

The new location in the heart of city’s tech hub is situated in Canada’s largest biotech cluster...

Spherium Biomed announced the completion of its Phase I/IIa clinical trial of Mucomel® for the prevention...

Asphalion, scientific and regulatory affairs consultancy, has opened its third office in Madrid managed by Dr André Mota...

Avinent has posted several research studies on its website that wereconducted in collaboration with renowned scientists and...

Hartmann presented its latest advances in negative-pressure wound therapy (NPWT)...

Compliance Services, a regulatory affairs consultancy for the health sector and member of CataloniaBio & HealthTech...

Eleven Catalan companies from the 3D printing and medical devices sectors participated in a mission to Boston (Massachusetts, United States), from 16 to 19 April, organised by the Government of Catalonia (through ACCIÓ) and the Catalonia Trade and Investment Office in Boston, with collaboration from CataloniaBio & HealthTech.

Over the four-day mission, Avinent, Diopma, Mastertec, Neos Surgery, Servocad Microtronics, Tractivus and Ventura Medical, plus the Institute for Bioengineering of Catalonia (IBEC), Hospital Clinic, Althaia Foundation and Fira de Barcelona, met with companies and organisations including Massachusetts General Hospital, Tufts Medical Center, Boston Scientific, Weitz Laboratory at Harvard University and Johnson ...

A delegation of eight Catalan companies from the biomedicine and health arena, most CataloniaBio & HealthTech members...

Reig Jofre has announced a €30 million investment and the triplication of the productive capacity of its Barcelona plant...

Palex Medical, a CataloniaBio & HealthTech member company, will be the exclusive distributor in Spain and...